INDICATION
EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.
Please see below for Important Safety Information for EPCLUSA.
FOR YOUR CHRONIC HCV PATIENTS, INCLUDING PEOPLE WHO INJECT DRUGS1
Featured patients
compensated by Gilead.
Scroll to see adherence data below
ONLY EPCLUSA HAS
100%
OVERALL CURE RATE (mITT) IN PEOPLE WHO INJECT DRUGS AMONG PANGENOTYPIC REGIMENS2,3
GT 1-4 NC/CC (n=97/97;
SIMPLIFY study)
mITT = modified intent-to-treat excludes 1 reinfection and 5 patients who did not meet virologic failure criteria [SVR rate 95% CI: 96%-100%].1,3
This post-hoc mITT analysis of patients from the SIMPLIFY trial was not in the original statistical plan and should be considered descriptive only. The mITT analysis is not presented in the EPCLUSA full Prescribing Information or the SIMPLIFY publication.
94%
OVERALL CURE RATE (ITT) IN PEOPLE WHO INJECT DRUGS WITH CHRONIC HCV1
GT 1-4 NC/CC (n=97/103;
SIMPLIFY study)
SVR12 was the primary endpoint in the SIMPLIFY study (HCV RNA <LLOQ 12 weeks after treatment completion). Achieving SVR12 is considered a virologic cure.1,4
SVR12 could not be determined in 6 patients because 4 were lost to follow-up, 1 died of an overdose, and 1 was reinfected with a phylogenetically different virus.1-3
SVR12 could not be determined in 6 patients because 4 were lost to follow-up, 1 died of an overdose, and 1 was reinfected with a phylogenetically different virus.1-3
ONLY EPCLUSA HAS
100%
CURE RATE (mITT) IN PEOPLE WITH IMPERFECT ADHERENCE IN A PWID-SPECIFIC STUDY2,3,5
(n=31/31; 95% CI: 89%-100%;
SIMPLIFY study)
Imperfect adherence = <90% adherence or >8 doses missed.2,6
mITT = modified intent-to-treat excludes 1 reinfection and 5 patients who did not meet virologic failure criteria [SVR rate 95% CI: 96%-100%]. Among the 6 excluded patients, 3 had <90% adherence.1,3
91%
CURE RATE (ITT) IN PEOPLE WITH IMPERFECT ADHERENCE IN A PWID-SPECIFIC STUDY1,2
(n=31/34; SIMPLIFY study)
Imperfect adherence = <90% adherence or >8 doses missed.2,6
SVR12 (cure) = HCV RNA <LLOQ 12 weeks after treatment completion.4
Overall median adherence: 94% (IQR 88‑98).2
a In SIMPLIFY, “people who inject drugs” was defined as those who had injected drugs within the 6 months prior to study initiation.1
ONLY EPCLUSA HAS
b Among first-line pangenotypic regimens.
BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.
EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.
Consult the full Prescribing Information for EPCLUSA for more information on potentially significant drug interactions, including clinical comments.
Please see full Prescribing Information for EPCLUSA, including BOXED WARNING.
BOXED WARNING: RISK OF HEPATITIS B
REACTIVATION
IN HCV/HBV COINFECTED PATIENTS
Test all patients for evidence of current or prior hepatitis B virus (HBV) infection
before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV
coinfected patients who were undergoing or had completed treatment with HCV
EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.
CC = compensated cirrhosis; CI = confidence interval; DAA = direct-acting antiviral; DDI = drug-drug interaction; GT = genotype; IQR = interquartile range; ITT = intent-to-treat; LLOQ = lower limit of quantification; mITT = modified intent-to-treat; NC = non-cirrhotic; SVR = sustained virologic response; SVR12 = sustained virologic response 12 weeks after treatment completion.
References: